---
title: "Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025"
description: "Aardvark Therapeutics Inc. will present new data on its obesity drug pipeline at ObesityWeek 2025 in Atlanta from November 4-7, 2025. The company will showcase investigational compounds ARD-101 and WE"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262236459.md"
published_at: "2025-10-22T12:00:28.000Z"
---

# Aardvark Therapeutics Unveils Positive Obesity Drug Data at ObesityWeek 2025

> Aardvark Therapeutics Inc. will present new data on its obesity drug pipeline at ObesityWeek 2025 in Atlanta from November 4-7, 2025. The company will showcase investigational compounds ARD-101 and WE-868, with presentations by CSO Timothy Kieffer and CEO Tien Lee on November 4. An investor webinar is scheduled for November 5 to discuss the data and updates on ARD-101’s development in Prader-Willi Syndrome, with an archived recording available for a month post-event.

Aardvark Therapeutics Inc. announced that it will present new data from its pipeline programs at ObesityWeek 2025, scheduled for November 4-7, 2025, in Atlanta, Georgia. The company will share poster presentations on its investigational compounds, including ARD-101, a TAS2R pan-agonist evaluated for its effects on weight gain in mice and hunger reduction in adults with obesity, and WE-868, an isoflavonoid modulator of oxidative metabolism with therapeutic potential in obesity and diabetes. The data will be presented by Chief Scientific Officer Timothy Kieffer, Ph.D., and Chief Executive Officer Tien Lee, M.D., on November 4, 2025. Additionally, Aardvark will host an investor webinar on November 5, 2025, to discuss the presented data and provide updates on ARD-101’s development in Prader-Willi Syndrome. The company will make an archived recording of the webinar available on its website for approximately one month after the event. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aardvark Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9549733-en) on October 22, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [AARD.US - Aardvark Therapeutics](https://longbridge.com/en/quote/AARD.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Aardvark Therapeutics 獲得倫理審查委員會（IRB）的批准，擴大了第三階段 HERO 試驗的參與資格 | Aardvark Therapeutics Inc. 已獲得機構審查委員會（IRB）對其第三階段 HERO 試驗修訂協議的批准，該試驗評估 ARD-101 在治療普拉德 - 威利綜合症中的過度飲食。該協議現在允許年僅 7 歲的兒童參與，將之 | [Link](https://longbridge.com/en/news/275461906.md) |
| 奧本海默以 ‘表現優異’ 評級開始覆蓋 Aardvark，因其在肥胖症領域的差異化業務 | Oppenheimer 對 Aardvark Therapeutics 啓動覆蓋，給予 “跑贏大盤” 評級，並設定 35 美元的目標價，顯示出潛在的股票增長。Aardvark 專注於普拉德 - 威利綜合症和肥胖症，預計即將發佈 ARD-10 | [Link](https://longbridge.com/en/news/270613899.md) |
| 忘掉 AI 股票：這家制藥巨頭正在通過 AI 主導藥物研發 | 而且還有多種方式可以將這項技術變現 | [Link](https://longbridge.com/en/news/276017486.md) |
| 斥資 185 億美元牽手石藥集團後，阿斯利康每股收益預增雙位數 | 阿斯利康預計 2026 年每股收益將實現兩位數增長，腫瘤藥物銷售強勁有望抵消糖尿病藥物專利到期影響。公司近期以高達 185 億美元引入石藥集團長效肽技術，加速佈局 GLP-1 減肥藥市場。儘管面臨美國藥價政策調整，公司通過協議獲得關税豁免。 | [Link](https://longbridge.com/en/news/275425282.md) |
| Questar Solutions 宣佈進行重大擴張，設立新的公司總部和亞特蘭大配送中心 | Questar Solutions 宣佈了一項重大擴展，將其公司總部和北坎頓倉庫遷至俄亥俄州一個更大的設施，遷移將於 2026 年 1 月 27 日生效。新的總部將提升運營效率和客户服務。此外，Questar 還將在喬治亞州亞特蘭大開設一個 | [Link](https://longbridge.com/en/news/275498183.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
